Tags Biotechnology

Tag: Biotechnology

Kalyagen Announces Attendance at the Fort Lauderdale Open with PGA Associate Jerrel Gill

AUSTIN, Texas, April 29, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen® is pleased to announce that it will be attending the Fort Lauderdale Open as part of its sponsorship of golf professional Jerrel Gill. The Open will be hosted at the Fort Lauderdale Country Club on May 2-3, 2022.

Kalyagen Announces Attendance at Paleo f(x) 2022 Conference

AUSTIN, Texas, April 27, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen is pleased to announce that it will be attending and hosting a booth (#121) at the upcoming Paleo f(x)™ 2022 conference to be held in Austin on April 29 - May 1. STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine

ROCHESTER, Minn., April 6, 2022 (SEND2PRESS NEWSWIRE) -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.

Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies

OKLAHOMA CITY, Okla., AUSTIN, Texas and MELBOURNE, Australia, April 6, 2022 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

Neurosoft Bioelectronics Receives Nearly $3 Million in Funding

GENEVA, Switzerland, and NEW YORK, N.Y., April 5, 2022 (SEND2PRESS NEWSWIRE) -- Neurosoft Bioelectronics, an early-stage company developing tools for unmet needs in epilepsy and tinnitus, was awarded nearly $3 million USD, from the SERI-Funded European Innovation Council Accelerator Grant and a share of the $165,000 USD through the European Research Council Proof-of-Concept Grant.

Key Entrepreneurs to Present at 2022 Bioelectronic Medicine Forum

NEW YORK, N.Y., March 28, 2022 (SEND2PRESS NEWSWIRE) -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that founders and CEOs of several promising bioelectronic medicine startups will present at the Fifth Annual Bioelectric Medicine Forum on April 5, 2022. The event will take place in New York City, although participation via Zoom videoconference will be accommodated.

Kalyagen Announces Supporting Partnership of Two South Florida PGA Events and PGA Associate Jerrel Gill

AUSTIN, Texas, March 10, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen® is pleased to announce that it is a supporting partner of two upcoming South Florida PGA Section events and golf professional Jerrel Gill. The two events are the South Florida PGA Foundation PGA HOPE Classic on May 12, 2022 and the South Florida Open on June 21-23, 2022.

Pure Transplant Solutions, LLC and Vall d’Hebron University Hospital Announce Research Collaboration

AUSTIN, Texas and BARCELONA, Spain, Feb. 15, 2022 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.

Pure Transplant Solutions, LLC and Oxford Immunotec, Ltd. Announce Exclusive Sublicense Agreement to Support Commercialization of Novel B Cell Measurement Assay...

AUSTIN, Texas and OXFORD, U.K., Dec. 7, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D.

Neurotech Reports Announces Launch of New Publication Serving Bioelectronic Medicine Industry

SAN FRANCISCO, Calif., Nov. 8, 2021 (SEND2PRESS NEWSWIRE) -- Neurotech Reports, the San Francisco, California publisher of market intelligence for the healthcare industry, announced the launch of a new monthly newsletter covering the bioelectronic medicine industry, one of the newest and fastest growing industry segments. The publication, BioElectRx Business Report, is the first industry newsletter devoted to bioelectronic medicine.

Kalyagen™ Announces Registration of STEMREGEN® in Spain, CEO at Madrid Stem Cell Symposium

AUSTIN, Texas, Oct. 12, 2021 (SEND2PRESS NEWSWIRE) -- Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau's, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.

iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal

STONY BROOK, N.Y., Sept. 10, 2021 (SEND2PRESS NEWSWIRE) -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.

Vyriad, Inc. Appoints Harry Hoffman to its Board of Directors

ROCHESTER, Minn., Aug. 24, 2021 (SEND2PRESS NEWSWIRE) -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company's board of directors.

KROST Acts as Exclusive Financial Advisor for Integrity Bio in Sale to Curia

LOS ANGELES, Calif., Aug. 11, 2021 (SEND2PRESS NEWSWIRE) -- Integrity Bio, Inc., a privately held formulation and fill-finish organization, was sold to Curia (formerly Albany Molecular Research, Inc. (AMRI)), a Contract Development and Manufacturing Organization (CDMO) and leading global provider of advanced contract research, development, and manufacturing solutions. KROST, a Los Angeles-based firm, acted as the exclusive financial advisor to Integrity Bio in the transaction.

Pure Transplant Solutions, LLC Announces Research Collaboration with the Department of Surgery at the University of Cambridge

AUSTIN, Texas and CAMBRIDGE, U.K., July 21, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The University of Cambridge Abdominal Transplant Centre at Addenbrooke's Hospital.

BioAustin Appoints New Leadership and Unveils An Expanded Strategic Focus In Central Texas As BioAustinCTX

AUSTIN, Texas, June 3, 2021 (SEND2PRESS NEWSWIRE) -- Life Science industry organization BioAustin today announced changes to its leadership team, brand positioning, and long-term strategy focused on facilitating the continued growth of the life science industry in Central Texas. Over the past several years, Austin and the Central Texas region have developed into one of the fastest-growing life science hubs in the U.S.

Pure MHC, LLC Announces Launch of Contract Research Service Division and Initial Collaboration Project with argenx

AUSTIN, Texas, March 31, 2021 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.

Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection

AUSTIN, Texas and LOOS, France, March 24, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Innobiochips (IBC).

Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens in Transplant...

AUSTIN, Texas and EVANSTON, Ill., March 17, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Northwestern University, a world leader in HLA DQ antigen research.

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

AUSTIN, Texas, March 16, 2021 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

FEATURED NEWS

NATIONAL NEWS